Eli Lilly and Company $LLY Shares Sold by Livforsakringsbolaget Skandia Omsesidigt

Livforsakringsbolaget Skandia Omsesidigt cut its stake in Eli Lilly and Company (NYSE:LLY) by 4.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 26,506 shares of the company’s stock after selling 1,200 shares during the period. Eli Lilly and Company makes up approximately 0.8% of Livforsakringsbolaget Skandia Omsesidigt’s holdings, making the stock its 22nd largest holding. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Eli Lilly and Company were worth $20,207,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Apexium Financial LP raised its holdings in Eli Lilly and Company by 1.9% during the third quarter. Apexium Financial LP now owns 1,905 shares of the company’s stock worth $1,453,000 after purchasing an additional 35 shares during the last quarter. Saratoga Research & Investment Management grew its holdings in Eli Lilly and Company by 65.1% in the third quarter. Saratoga Research & Investment Management now owns 61,459 shares of the company’s stock valued at $46,893,000 after purchasing an additional 24,226 shares during the last quarter. Financial Engines Advisors L.L.C. grew its holdings in Eli Lilly and Company by 37.5% in the third quarter. Financial Engines Advisors L.L.C. now owns 2,982 shares of the company’s stock valued at $2,275,000 after purchasing an additional 813 shares during the last quarter. Palisade Asset Management LLC increased its position in shares of Eli Lilly and Company by 3.1% in the third quarter. Palisade Asset Management LLC now owns 18,889 shares of the company’s stock valued at $14,412,000 after buying an additional 566 shares in the last quarter. Finally, FSA Wealth Management LLC increased its position in shares of Eli Lilly and Company by 4.0% in the third quarter. FSA Wealth Management LLC now owns 309 shares of the company’s stock valued at $236,000 after buying an additional 12 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Positive pediatric Phase‑3 results for EBGLYSS (lebrikizumab) expand Lilly’s immunology franchise and reduce execution risk on non‑GLP pipeline growth—a clear constructive catalyst for longer‑term revenue diversification. Lilly EBGLYSS Phase 3 Pediatric Results
• Positive Sentiment: Several Wall Street firms remain bullish—some raising targets and highlighting Zepbound/Mounjaro momentum and distribution initiatives (e.g., Employer Connect)—which supports medium‑term sales and margin expectations. Wall Street Firms Turn Bullish on Eli Lilly
• Neutral Sentiment: Disclosure that a member of Congress purchased LLY shares is a data point that can increase watchlist activity but is not a fresh fundamental catalyst. Members of Congress Bought These 5 Stocks—Should You?
• Negative Sentiment: HSBC downgraded LLY to “reduce” (cutting its price target to $850) citing pricing pressure, rising competition, and what it sees as overstated obesity‑market growth—this downgrade triggered selling and repricing of growth expectations. Eli Lilly Analyst Flags Overhyped Obesity Drug Expectations
• Negative Sentiment: Competitive threats intensified after reports of a new GLP‑1 oral pill showing strong weight‑loss data and commentary about Novo Nordisk rivalry; investors are re‑assessing Lilly’s pricing power and market share durability. Structure Weight‑Loss Pill Results Rival Novo, Lilly Treatments
• Negative Sentiment: Market writeups highlight valuation risk: with high multiples already priced for continued GLP‑1 growth, any downgrade or slower uptake triggers outsized downside as investors rotate away from stretched growth names. Why Eli Lilly Stock Just Dropped

Eli Lilly and Company Stock Down 5.9%

LLY opened at $931.03 on Wednesday. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The firm has a market cap of $879.65 billion, a P/E ratio of 40.57, a PEG ratio of 1.15 and a beta of 0.40. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The business’s fifty day simple moving average is $1,033.54 and its 200 day simple moving average is $955.52.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter last year, the business posted $5.32 EPS. The firm’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LLY has been the topic of several recent research reports. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. BMO Capital Markets restated an “outperform” rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a report on Thursday, February 5th. Argus lifted their target price on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,313.00 price target on shares of Eli Lilly and Company in a report on Thursday, March 5th. Finally, The Goldman Sachs Group set a $1,260.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,221.44.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.